Cyclophosphamide therapy in patients with advancing breast cancer following adrenalectomy and 5-fluorouracil.
D000309:Adrenal Insufficiency / Q000139:chemically induced; D000315:Adrenalectomy; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy / Q000628:therapy*; D003348:Cortisone / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003556:Cystitis / Q000139:chemically induced; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors
D003520:Cyclophosphamide; D005472:Fluorouracil; D003348:Cortisone; D006854:Hydrocortisone